These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

67 related articles for article (PubMed ID: 11526815)

  • 21. Parkinsonism as a manifestation of multiple sclerosis.
    Folgar S; Gatto EM; Raina G; Micheli F
    Mov Disord; 2003 Jan; 18(1):108-10. PubMed ID: 12518309
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Nefazodone and akathisia.
    Eberstein S; Adler LA; Angrist B
    Biol Psychiatry; 1996 Oct; 40(8):798-9. PubMed ID: 8894074
    [No Abstract]   [Full Text] [Related]  

  • 23. Perceptual disturbances associated with low-dose bupropion sustained-release treatment.
    Liu CY; Chien YS
    J Clin Psychopharmacol; 2007 Oct; 27(5):543-4. PubMed ID: 17873707
    [No Abstract]   [Full Text] [Related]  

  • 24. Combined bupropion-levodopa-trazodone therapy of sleep-related eating and sleep disruption in two adults with chemical dependency.
    Schenck CH; Mahowald MW
    Sleep; 2000 Aug; 23(5):587-8. PubMed ID: 10947025
    [No Abstract]   [Full Text] [Related]  

  • 25. Eight-week, placebo-controlled, double-blind comparison of the antidepressant efficacy and tolerability of bupropion XR and venlafaxine XR.
    Hewett K; Chrzanowski W; Schmitz M; Savela A; Milanova V; Gee M; Krishen A; Millen L; Leary MO; Modell J
    J Psychopharmacol; 2009 Jul; 23(5):531-8. PubMed ID: 18635695
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Effectiveness of a quantitative electroencephalographic biomarker for predicting differential response or remission with escitalopram and bupropion in major depressive disorder.
    Leuchter AF; Cook IA; Gilmer WS; Marangell LB; Burgoyne KS; Howland RH; Trivedi MH; Zisook S; Jain R; Fava M; Iosifescu D; Greenwald S
    Psychiatry Res; 2009 Sep; 169(2):132-8. PubMed ID: 19709754
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Outcomes on the pharmacopsychometric triangle in bupropion-SR vs. buspirone augmentation of citalopram in the STAR*D trial.
    Bech P; Fava M; Trivedi MH; Wisniewski SR; Rush AJ
    Acta Psychiatr Scand; 2012 Apr; 125(4):342-8. PubMed ID: 22077211
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Bupropion in the management of apathy.
    Corcoran C; Wong ML; O'Keane V
    J Psychopharmacol; 2004 Mar; 18(1):133-5. PubMed ID: 15107198
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Double-blind, placebo-controlled evaluation of extended-release bupropion in elderly patients with major depressive disorder.
    Hewett K; Chrzanowski W; Jokinen R; Felgentreff R; Shrivastava RK; Gee MD; Wightman DS; O'Leary MC; Millen LS; Leon MC; Briggs MA; Krishen A; Modell JG
    J Psychopharmacol; 2010 Apr; 24(4):521-9. PubMed ID: 19164492
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Visual field "shimmering" associated with nefazodone.
    Greenberg WM
    J Clin Psychiatry; 1999 Feb; 60(2):124. PubMed ID: 10084642
    [No Abstract]   [Full Text] [Related]  

  • 31. Parkinsonism with multiple cysts in the bilateral striata.
    Norimoto K; Kiuchi K; Morikawa M; Inoue Y; Kosaka J; Inoue M; Kishimoto T
    Psychogeriatrics; 2011 Sep; 11(3):166-70. PubMed ID: 21951957
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Modafinil-induced reversible hyperkinetic nondystonic movement disorder in a patient with major depressive disorder.
    Luborzewski A; Regen F; Schindler F; Anghelescu I
    J Neuropsychiatry Clin Neurosci; 2006; 18(2):248-9. PubMed ID: 16720809
    [No Abstract]   [Full Text] [Related]  

  • 33. Cognitive predictors of treatment response to bupropion and cognitive effects of bupropion in patients with major depressive disorder.
    Herrera-Guzmán I; Gudayol-Ferré E; Lira-Mandujano J; Herrera-Abarca J; Herrera-Guzmán D; Montoya-Pérez K; Guardia-Olmos J
    Psychiatry Res; 2008 Jul; 160(1):72-82. PubMed ID: 18501971
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Bupropion-related sexual dysfunction and possible management in a fresh patient with major depressive disorder.
    Lai CH
    J Neuropsychiatry Clin Neurosci; 2014 Apr; 26(2):E18-9. PubMed ID: 24763775
    [No Abstract]   [Full Text] [Related]  

  • 35. Fatigue as a core symptom in major depressive disorder: overview and the role of bupropion.
    Pae CU; Lim HK; Han C; Patkar AA; Steffens DC; Masand PS; Lee C
    Expert Rev Neurother; 2007 Oct; 7(10):1251-63. PubMed ID: 17939764
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Bupropion normalizes cognitive performance in patients with depression.
    Gualtieri CT; Johnson LG
    MedGenMed; 2007 Jan; 9(1):22. PubMed ID: 17435629
    [No Abstract]   [Full Text] [Related]  

  • 37. Clinical Experience With High-Dosage Pramipexole in Patients With Treatment-Resistant Depressive Episodes in Unipolar and Bipolar Depression.
    Fawcett J; Rush AJ; Vukelich J; Diaz SH; Dunklee L; Romo P; Yarns BC; Escalona R
    Am J Psychiatry; 2016 Feb; 173(2):107-11. PubMed ID: 26844792
    [No Abstract]   [Full Text] [Related]  

  • 38. Analysis of 34 candidate genes in bupropion and placebo remission.
    Tiwari AK; Zai CC; Sajeev G; Arenovich T; Müller DJ; Kennedy JL
    Int J Neuropsychopharmacol; 2013 May; 16(4):771-81. PubMed ID: 22947179
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Combination therapy in the treatment of major depressive disorder complicated by fibromyalgia and menopause.
    Clayton AH; Kaltsounis-Puckett J
    Psychosomatics; 2002; 43(6):491-3. PubMed ID: 12444233
    [No Abstract]   [Full Text] [Related]  

  • 40. Parkinsonism in a nursing home: underrecognition.
    Friedman JH; Fernandez HH; Trieschmann MM
    J Geriatr Psychiatry Neurol; 2004 Mar; 17(1):39-41. PubMed ID: 15018697
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 4.